Compare Amgen, Inc. (AMGN) vs Bitwise Crypto Industry Innovators ETF (BITQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Bitwise Crypto Industry Innovators ETF — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Bitwise Crypto Industry Innovators ETF trades at $23.75. The key difference: Amgen, Inc. pays a 2.77% dividend while Bitwise Crypto Industry Innovators ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | BITQ | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Crypto-linked |
52-Week High | $388.16 | $30.43 |
52-Week Low | $271.18 | $16.74 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BITQ is trading at $23.93, down 0.91% on the day, with technical indicators showing a bearish trend across moving averages and oscillators. The stock faces resistance at $24 and support at $23. Recent news highlights investor concerns about cryptocurrency exposure through ETFs, though some analysts see potential in crypto industry innovators during market recoveries.
The outlook remains cautious due to weak technical momentum and sector volatility. Investment opportunity exists for those betting on long-term crypto industry growth, but risks include regulatory uncertainty and market sentiment swings. Current levels near support may attract contrarian buyers if broader crypto markets stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →
